Evidence map›Paper›PMID 35436985›Full record

ArticleCell death & disease2022

Cancer cells adapt FAM134B/BiP mediated ER-phagy to survive hypoxic stress.

Sandhya Chipurupalli, Raja Ganesan, Giulia Martini, Luigi Mele, Alessio Reggio, Marianna Esposito, Elango Kannan, Vigneshwaran Namasivayam, Paolo Grumati, Vincenzo Desiderio and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. FAM134B controls collagen I dynamics in hepatic stellate cell-driven fibrosis.American journal of physiology. Gastrointestinal and liver physiology · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 5 countries.

Sandhya ChipurupalliCellular-Stress and Immune Response Laboratory, Center for Cancer Biology, University of South Australia, Adelaide, Australia.
Raja GanesanCellular-Stress and Immune Response Laboratory, Center for Cancer Biology, University of South Australia, Adelaide, Australia.ORCID 0000-0002-5408-0478
Giulia MartiniMedical Oncology, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Luigi MeleDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Alessio ReggioTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.
Marianna EspositoTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.ORCID 0000-0003-1151-7913
Elango KannanDepartment of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, India.
Vigneshwaran NamasivayamPharmaceutical Institute, Pharmaceutical Chemistry II, University of Bonn, Bonn, Germany.ORCID 0000-0003-3031-3377
Paolo GrumatiTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.ORCID 0000-0002-9942-9389
Vincenzo DesiderioDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. vincenzo.desiderio@unicampania.it.ORCID 0000-0003-1819-6083
Nirmal RobinsonCellular-Stress and Immune Response Laboratory, Center for Cancer Biology, University of South Australia, Adelaide, Australia. nirmal.robinson@unisa.edu.au.ORCID 0000-0002-7361-9491
Telethon Institute Of Genetics And Medicine · ITUniversity of Campania "Luigi Vanvitelli" · ITJSS Academy of Higher Education and Research · INUniversity of South Australia · AUUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the tumor microenvironment, cancer cells experience hypoxia resulting in the accumulation of misfolded/unfolded proteins largely in the endoplasmic reticulum (ER). Consequently, ER proteotoxicity elicits unfolded protein response (UPR) as an adaptive mechanism to resolve ER stress. In addition to canonical UPR, proteotoxicity also stimulates the selective, autophagy-dependent, removal of discrete ER domains loaded with misfolded proteins to further alleviate ER stress. These mechanisms can favor cancer cell growth, metastasis, and long-term survival. Our investigations reveal that during hypoxia-induced ER stress, the ER-phagy receptor FAM134B targets damaged portions of ER into autophagosomes to restore ER homeostasis in cancer cells. Loss of FAM134B in breast cancer cells results in increased ER stress and reduced cell proliferation. Mechanistically, upon sensing hypoxia-induced proteotoxic stress, the ER chaperone BiP forms a complex with FAM134B and promotes ER-phagy. To prove the translational implication of our mechanistic findings, we identified vitexin as a pharmacological agent that disrupts FAM134B-BiP complex, inhibits ER-phagy, and potently suppresses breast cancer progression in vivo.

Indexed as

AutophagyBreast NeoplasmsEndoplasmic ReticulumEndoplasmic Reticulum StressFemaleHumansHypoxiaMembrane ProteinsTumor MicroenvironmentMembrane Proteins

Identifiers

PMID35436985
PMCPMC9016075
OpenAlexW4223948344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.